CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled / 35 target
Drug / intervention
Aquamindrug
Likely dose
Aquamin 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04855799
NCT04855799Phase 2CompletedOn Track (0.6/mo)Completion was 27mo ago
CompareCT.gov

Direct Measurement of Gastrointestinal Permeability Change in Response to Aquamin®

James Varani·interventional·Posted Apr 22, 2021·Updated Jun 8, 2026

In Brief

A Phase 2 clinical trial evaluating Aquamin for Ulcerative Colitis and 2 related conditions. Completed, enrolled 35 participants across 1 site.

Detailed Summary

This trial is being completed to learn about how Aquamin® affects gastrointestinal permeability, or the control of material passing from inside the gastrointestinal tract through the gut wall into the rest of the body, in people with ulcerative colitis (UC), Irritable Bowel Syndrome with diarrhea (IBS-D), and in healthy individuals.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis, Healthy, Irritable Bowel Syndrome With Diarrhea
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedApr 22, 2021
Enrollment StartNov 2, 2021
Primary CompletionMar 11, 2024
Study CompletionMar 25, 2024
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 5.2 years ago

Arms & Interventions

Aquamin®experimental

Drug: Aquamin

Interventions

Aquamindrug

Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).